focus -WSS

focus

author：focus 2025-10-01 23:02:36 - browse：381

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Food as medicine: Medically tailored meals may get standardized

explore

focus

knowledge

WSS

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Decaf coffee targeted by food safety group under obscure FDA rule

Patient advocates debate FDA's accelerated approval process

The Biogen Aduhelm mess could happen again

Gene therapy for Afghan refugees’ infant will be fully covered

A protest over insulin prices is seen as a fight for life

explore

focus

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA's naming rule on biosimilars has undermined competition

Cancer drug shortages should be causing more outrage

Bernie brings in new pharma CEOs to talk drug prices

Cancer drug shortages should be causing more outrage

Padmanee Sharma of MD Anderson at center of lawsuit over credit

How one medical school became remarkably diverse

Why the world’s most expensive drug might be worth the price

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Top private equity targets in 2023: cardiology, clinical trials, lasers

hotspot

Devoted Health’s losses in Medicare Advantage persist

Patient advocates debate FDA's accelerated approval process

Decaf coffee targeted by food safety group under obscure FDA rule

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Unique patient identifier: Experts argue the benefits, pitfalls

Readout Newsletter: Amgen, Regeneron, BGI Group and more

explore

focus

knowledge

Wikipedia